Key Takeaways BPC-157 units depend on both vial strength and total diluent added
Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects
Our personalised plans mean you get treatments tailored specifically to your needs
Shah, R., Reyes-Gordillo, K., Cheng, Y., Varatharajalu, R., Ibrahim, J., & Lakshman, M
Note: Individual results may vary, and combining injections with a balanced diet and exercise will support your results
Any cloudiness, milkiness, or visible turbidity indicates either bacterial contamination or peptide aggregation, both of which render the solution unusable
